Research

CENTER FOR INFECTIOUS DISEASE POLICY AND RESEARCH by Lisa Schnirring     July 20, 2015

Tekmira Pharmaceuticals  announced that it has suspended development of TKM-Ebola, a drug cocktail that showed disappointing human trial results in West Africa, as a convalescent plasma trial at a Doctors Without Borders (MSF) facility in Guinea proceeded with no ill effects in patients so far...

In suspending TKM-Ebola development, the company said that a joint reevaluation of its contract with the US Department of Defense is under way.

In another development, MSF said a convalescent serum trial at its facility in Nongo, Guinea, has enrolled 101 people over the last few months, with no ill effects reported so far, according to a Jul 17 update on the outbreak. Patients at the Nongo treatment unit have the option to receive plasma donated by Ebola survivors....

Meanwhile, detailed testing at a Swiss hospital on a 43-year-old doctor infected with Ebola in Sierra Leone found that viral decay occurred in two phases, once starting 72 hours after symptom onset before any antiviral interventions, with acceleration in viral load decay after ZMAb infusion and oral favipiravir treatments began..

Read complete article.

NEW YORK TIMES  by Sheri Fink                   July 10, 2015

A resurgence of Ebola in the last week in Liberia, which had been declared free of the disease, may have originated with a survivor still carrying the virus, according to scientists who analyzed the genetic sequence of the virus from the body of a 17-year-old Liberian boy who died of Ebola last week.

The boy’s virus did not match strains still circulating in the continuing outbreak in Guinea and Sierra Leone, meaning he was unlikely to have caught the virus through cross-border travel.

LANCET by Patrick G. T. Walker and others                               Volume 15, No. 7, p825–832, July 2015
The ongoing Ebola epidemic in parts of west Africa largely overwhelmed health-care systems in 2014, making adequate care for malaria impossible and threatening the gains in malaria control achieved over the past decade. We quantified this additional indirect burden of Ebola virus disease.

We estimated the number of cases and deaths from malaria in Guinea, Liberia, and Sierra Leone from Demographic and Health Surveys data for malaria prevalence and coverage of malaria interventions before the Ebola outbreak. We then removed the effect of treatment and hospital care to estimate additional cases and deaths from malaria caused by reduced health-care capacity and potential disruption of delivery of insecticide-treated bednets. We modelled the potential effect of emergency mass drug administration in affected areas on malaria cases and health-care demand....

CANADIAN PRESS  by  Helen Branswell                       June 19, 2015

TORONTO -- A Canadian company that had been developing an Ebola drug says a clinical trial of the experimental product has been stopped.

Tekmira Pharmaceuticals says the trial was halted because it seemed clear that continuing was not likely to show that the drug works.

The drug is called TKM-Ebola. It was being tested with Ebola patients in Sierra Leone.

Read complete story.
http://www.ctvnews.ca/health/trial-of-canadian-ebola-drug-stopped-no-overall-benefit-shown-1.2430501